January 04, 2016.
Following the arrest on December 17 of former CEO Martin Shkreli, KaloBios Pharmaceuticals (South San Francisco, CA) filed for bankruptcy last week. According to Bloomberg Business, the company plans to use the bankruptcy to buy time to implement its restructuring plans. Shkreli, who took charge of KaloBios just a month ago, was arrested on fraud charges related to his position at his former company, Retrophin. KaloBios fired the controversial CEO shortly after his arrest. http://www.bloomberg.com/news/articles/2015-12-30/shkreli-s-former-biotech-company-kalobios-files-for-bankruptcy-iisup3fw
The Impact of Artificial Intelligence on the Creation of Medicines
October 24th 2024Najat Khan, chief R&D officer, chief commercial officer, Recursion, and Fred Hassan, director, Warburg Pincus, discuss how artificial intelligence can help reduce healthcare costs at the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.
Plan Ahead: Mastering Your AI Budget for 2025 Success
October 9th 2024Generative AI is just one part of the artificial intelligence and machine learning that is being used by life science organizations, emerging as a major area of interest and an area in which costs and ROI are still largely unknown.